Rayence Co

Rayence Co Net Debt / EBITDA

The Net Debt to EBITDA of Rayence Co (228850.KQ) as of Oct 23, 2026 is -16.39. In the previous year, Net Debt to EBITDA was -6.86 — a change of 138.83% (lower).

Net Debt / EBITDA

-16.39

YoY

138.83%

Last updated:

Net Debt to EBITDA of Rayence Co is 2024 -16.39 . Net Debt to EBITDA of Rayence Co was 2023 -6.86 . It decreases by 138.83% lower compared to the previous year.

The Rayence Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
-4.68 KRW
Jan 1, 2018
-4.31 KRW
Jan 1, 2019
-3.98 KRW
Jan 1, 2020
-25.54 KRW
Jan 1, 2021
-5.04 KRW
Jan 1, 2022
-5.41 KRW
Jan 1, 2023
-6.86 KRW
Jan 1, 2024
-16.39 KRW
The Rayence Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-16.39+138.83%
-6.86+26.78%
-5.41+7.35%
-5.04-80.25%
-25.54+541.15%
-3.98-7.56%
-4.31-7.87%
-4.68+11.82%
-4.18-7,914.89%
0.05-90.23%
0.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Net Debt to EBITDA of Rayence Co is -16.39 in 2024.

Net Debt to EBITDA of Rayence Co changed from -6.86 to -16.39, representing a 138.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Rayence Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Rayence Co

All Key Metrics — Rayence Co